Comparison · NCT01014442-sae
MMF - Cystic Fibrosis vs MMF - COPD, Emphysema, IPF, or A1AD: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MMF - Cystic Fibrosis vs MMF - COPD, Emphysema, IPF, or A1AD: serious adverse events. Trial comparisons, record NCT01014442-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01014442-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.394 | 0.247 | 0.563 | wilson | |
| Risk in group 2 | 0.4 | 0.256 | 0.564 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00606 | -0.227 | 0.216 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.985 | 0.548 | 1.77 | log | |
| Odds ratio, group 1 over group 2 | 0.975 | 0.369 | 2.58 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on MMF - Cystic Fibrosis than on MMF - COPD, Emphysema, IPF, or A1AD | 165 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MMF - Cystic Fibrosis | Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation. | 13 | 33 | EG000 |
| Group 2 | MMF - COPD, Emphysema, IPF, or A1AD | Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90. | 14 | 35 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From baseline up to Day 90
Source ClinicalTrials.gov
Trial
- Title
- A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
- NCT number
- NCT01014442
- Phases
- PHASE3
- Conditions
- Lung Transplantation
- Interventions
- mycophenolate mofetil
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2017-02-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01014442?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01014442-sae